RxDoctor Payments Data

Antonio Christophy, DO

Advanced Heart Failure and Transplant Cardiology · la Mesa, CANPI 1871897678

Payments from drug & device makers

$25,390in general payments, 2019–2025

Across 308 payments — averaging $82.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Cvrx, Inc.$5K
  • Abbott$4K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Abiomed$582
  • Medtronic$355
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$3,60014%
  • Speaking & faculty fees$11,15044%
  • Travel & lodging$1,4046%
  • Food & beverage$9,02236%
  • Education$2141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,390 in reported general payments places this provider in the 40th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$3,799
Medicare patients
33
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$183,139
EntrestoSacubitril/Valsartan108$122,737
JardianceEmpagliflozin216$105,789
OzempicSemaglutide58$42,940
PradaxaDabigatran Etexilate Mesylate143$40,512
BrilintaTicagrelor17$15,082
Amiodarone Hcl93$2,634
Potassium Chloride98$2,623
Metoprolol Tartrate215$2,248
Atorvastatin Calcium175$2,164
Spironolactone138$1,673
Bumetanide34$1,660
Metoprolol Succinate134$1,651
Furosemide133$1,641
Losartan Potassium130$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$183,139130 claims
Boehringer IngelheimJardiance, Pradaxa$219$146,301359 claims
NovartisEntresto$167$122,737108 claims
Novo NordiskOzempic$283$42,94058 claims
AstraZenecaBrilinta$12,183$15,08217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →